Human Breast Cancer Cell Line Surface Antigens and SLT-1 Sensitivity
| Cell Lines . | Dx . | SLT-R . | Ber-EP4 . | M38/MUC1 . | CD50 Values . |
|---|---|---|---|---|---|
| Hs578T | CAR | − | − | ++ | ND |
| MDA-MB-330 | LOB | − | − | − | ND |
| MDA-MB-468 | IDC | − | − | +++ | >10 μg/mL |
| CAMA-1 | AC | − | +++ | +++ | >10 μg/mL |
| BT-474 | IDC | − | +++ | +++ | ND |
| BT-20 | IDC | + | − | + | ND |
| DU4475 | MET (skin) | + | +++ | +++ | ND |
| MDA-MB-134 | IDC | + | +++ | ++ | ND |
| MDA-MB-435S | IDC | + | − | ++ | ND |
| ZR-75 | IDC | + | ++ | +++ | ND |
| MCF-7 | IDC | +/++ | +++ | ++/+++ | 2 ng/mL |
| MDA-MB-157 | MED | ++ | +++ | +++ | ND |
| SKBR3 | AC | ++ | +++ | ++/+++ | >10 μg/mL |
| JS-1 | MET (bone) | ++ | − | − | 40 ng/mL |
| MDA-MB-231 | AC | +++ | + | +++ | 0.01 ng/mL |
| MDA-MB-469 | ND | +++ | +++ | +++ | 0.01 ng/mL |
| T47D | IDC | +++ | +++ | +++ | 0.7 μg/mL |
| UACC-812 | IDC | +++ | +++ | +++ | ND |
| Cell Lines . | Dx . | SLT-R . | Ber-EP4 . | M38/MUC1 . | CD50 Values . |
|---|---|---|---|---|---|
| Hs578T | CAR | − | − | ++ | ND |
| MDA-MB-330 | LOB | − | − | − | ND |
| MDA-MB-468 | IDC | − | − | +++ | >10 μg/mL |
| CAMA-1 | AC | − | +++ | +++ | >10 μg/mL |
| BT-474 | IDC | − | +++ | +++ | ND |
| BT-20 | IDC | + | − | + | ND |
| DU4475 | MET (skin) | + | +++ | +++ | ND |
| MDA-MB-134 | IDC | + | +++ | ++ | ND |
| MDA-MB-435S | IDC | + | − | ++ | ND |
| ZR-75 | IDC | + | ++ | +++ | ND |
| MCF-7 | IDC | +/++ | +++ | ++/+++ | 2 ng/mL |
| MDA-MB-157 | MED | ++ | +++ | +++ | ND |
| SKBR3 | AC | ++ | +++ | ++/+++ | >10 μg/mL |
| JS-1 | MET (bone) | ++ | − | − | 40 ng/mL |
| MDA-MB-231 | AC | +++ | + | +++ | 0.01 ng/mL |
| MDA-MB-469 | ND | +++ | +++ | +++ | 0.01 ng/mL |
| T47D | IDC | +++ | +++ | +++ | 0.7 μg/mL |
| UACC-812 | IDC | +++ | +++ | +++ | ND |
Results from the flow cytometric analysis of breast cancer cell lines for surface expression of SLT-R, Ber-EP4, and M38/MUC1. Also shown are CD50 values derived from Fig 1. Expression of surface antigen in terms of percentage of cells staining positively for a marker is defined as negative or − (0% to 14%), weak or + (15% to 40%), intermediate or ++ (41% to 70%), and strong or +++ (71% to 100%).
Abbreviations: Dx, morphological diagnosis42; CAR, carcinosarcoma; LOB, lobular carcinoma; IDC, intraductal carcinoma; MET, metastatic carcinoma; MED, medullary carcinoma; AC, adenocarcinoma; CD50, dose of SLT-1 required to kill 50% of cells; ND, not determined.